{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Maximum tolerated dose (MTD) defined as follows: At first dose level, if greater than 1 out of 3 patients or greater than 1 out of 6 patients experience dose limiting toxicity (DLT), the dose level exceeds the maximum tolerated dose (MTD). Dose limiting toxicity (DLT) defined as toxicities graded in severity according to the guidelines outlined in the NCI-Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.","groups":[{"description":"Induction of Lenalidomide 25 mg orally Days 1-14; Bortezomib 1.3 mg/m\\^2 intravenous Days 1, 4, 8 and 11; Dexamethasone 20 mg orally Days 1, 2, 4, 5, 8, 9, 11, 12. Siltuximab 11 mg/kg intravenous Day 1. If delayed transplant, induction therapy continued up to 2 cycles beyond achieving a CR/nCR then transition to maintenance therapy (Lenalidomide at last tolerated dose Day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg). Siltuximab 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy. Bortezomib at last tolerated dose Day 1 and Day 8 Dexamethasone at last tolerated dose or 20 mg weekly.","id":"OG000","title":"Siltuximab + Bortezomib + Lenalidomide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"21 days","title":"Maximum Tolerated Dose (MTD) of Siltuximab","type":"PRIMARY","unitOfMeasure":"mg/kg"}